BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
23 Outubro 2023 - 7:45AM
MAINZ, Germany, October 23, 2023 (GLOBE
NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the
Company”) will announce its financial results for the third quarter
2023 on Monday, November 6th, 2023. BioNTech invites investors and
the general public to join a conference call and webcast with
investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET)
to report its financial results and provide a corporate update for
the third quarter 2023.
To access the live conference call via
telephone, please register via this link. Once registered, dial-in
numbers and a pin will be provided. It is recommended to register
at least a day in advance. The slide presentation and audio of the
webcast will be available via this link.
Additionally, BioNTech will host the second
edition of the Company’s Innovation Series on Tuesday, November
7th, 2023. The event will provide an update on BioNTech’s clinical
progress across its pipeline and provide a deep dive into
scientific and technological innovations from its proprietary
research engine.
Investors and the interested public are invited
to join a webcast with investment analysts at 9:00 a.m. ET (3:00
p.m. CET). The slide presentation and audio of the webcast will be
available via this link.
Participants may also access the slides and the
webcast of the conference call as well as the second edition of the
Innovation Series via the “Events & Presentations” page of the
Investor Relations section of the Company’s website at
www.BioNTech.com. A replay of both the webcast for the third
quarter financial results 2023 as well as for the second edition of
the Innovation Series will be available shortly after the
conclusion of the respective calls and archived on the Company’s
website for 30 days following each call.
About BioNTechBiopharmaceutical New
Technologies (BioNTech) is a next generation immunotherapy company
pioneering novel therapies for cancer and other serious diseases.
The Company exploits a wide array of computational discovery and
therapeutic drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells, bispecific
immune checkpoint modulators, targeted cancer antibodies and small
molecules. Based on its deep expertise in mRNA vaccine development
and in-house manufacturing capabilities, BioNTech and its
collaborators are developing multiple mRNA vaccine candidates for a
range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global pharmaceutical collaborators, including
DualityBio, Fosun Pharma, Genentech, a member of the Roche Group,
Genevant, Genmab, OncoC4, Regeneron, Sanofi, and Pfizer.For more
information, please visit www.BioNTech.com.
Contacts
Investor RelationsVictoria Meissner,
M.D.+1 617 528 8293Investors@biontech.de
Media RelationsJasmina Alatovic+49
(0)6131 9084 1513Media@biontech.de
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
BioNTech (NASDAQ:BNTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024